Effect of probiotics on patients with NAFLD

Effect of probiotics supplementation on blood profile on NAFLD patients

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT2012122911920N1

Enrollment

Registered

2013-05-19

Start date

2013-05-31

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non Alchoholic Fatty Liver Disease. Fatty (change of) liver, not elsewhere classified

Interventions

Intervention 1: Control: Placebo Group receiving capsules once daily, for eight weeks. Intervention 2: Intervention: patients in the treatment group received probiotic capsules (Lactobacillus, Bifidob

Treatment - Drugs

Control: Placebo Group receiving capsules once daily, for eight weeks.

Intervention: patients in the treatment group received probiotic capsules (Lactobacillus, Bifidobacter, Streptococcus) once daily for 8 weeks.

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: patients with NAFLD; the age range was 18 to 65 years old. Exclusion criteria: patients with NAFLD that used supplemental probiotics of probiotic foods during last 3 monthes; also those used tobacco and alcohol; patients with cardiovascular diseases, chronic liver and kidney diseases, Wilson disease, Hemochromatosis; people with low immune system ability (autoimmune) and pregnant or lactating women.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Malodialdehyde (MDA). Timepoint: Before and after Intervention. Method of measurement: ELISA.;TAC. Timepoint: Before and after Intervention. Method of measurement: ELISA.;Serum Insulin Levels. Timepoint: Before and After Intervention. Method of measurement: ELISA.;IL-6. Timepoint: Before and After Intervention. Method of measurement: ELISA.;Serum Glucose. Timepoint: Before and after Intervention. Method of measurement: Autoanalyzer.;Lipid Profile ( Tg,Total Chol, LDL-C, HDL-C ). Timepoint: Before and After Intervention. Method of measurement: Autoanalyzer.;TNF-a. Timepoint: Before and after Intervention. Method of measurement: ELISA.;OxLDL. Timepoint: Before and after Intervention. Method of measurement: ELISA.;ALT. Timepoint: Before and after Intervention. Method of measurement: autoanalyzer.;AST. Timepoint: Before and after Intervention. Method of measurement: autoanalyzer.	—

Measure

Time frame

Malodialdehyde (MDA). Timepoint: Before and after Intervention. Method of measurement: ELISA.;TAC. Timepoint: Before and after Intervention. Method of measurement: ELISA.;Serum Insulin Levels. Timepoint: Before and After Intervention. Method of measurement: ELISA.;IL-6. Timepoint: Before and After Intervention. Method of measurement: ELISA.;Serum Glucose. Timepoint: Before and after Intervention. Method of measurement: Autoanalyzer.;Lipid Profile ( Tg,Total Chol, LDL-C, HDL-C ). Timepoint: Before and After Intervention. Method of measurement: Autoanalyzer.;TNF-a. Timepoint: Before and after Intervention. Method of measurement: ELISA.;OxLDL. Timepoint: Before and after Intervention. Method of measurement: ELISA.;ALT. Timepoint: Before and after Intervention. Method of measurement: autoanalyzer.;AST. Timepoint: Before and after Intervention. Method of measurement: autoanalyzer.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSepideh Abbaszadeh

Baqiyatallah University of Medical Sciences

dr_s_abbaszadeh@yahoo.comabbaszadeh@bmsu.ac.ir+98 21 8804 0153

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026